drugset / Trial / NCT02579642

Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy

NCT02579642 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Ketamine has been used successfully as the sole medication for anesthesia in the setting of electroconvulsive therapy (ECT), and has more recently been studied as an adjunct agent in combination with propofol (the most commonly used anesthetic agent) to induce anesthesia for ECT. New literature postulates an anti-depressant effect of ketamine, which in ECT specifically may be helpful with regards to the overall goals of therapy (i.e. ECT indicated for severe or treatment-resistant depression). Current research focusing on ketamine with respect to its anti-depressant effect suggests it may even represent an alternative to ECT. This study will seek to determine whether ketamine when used in low-doses as an adjunct to propofol-based anesthesia for ECT has anti-depressant effects and whether it influences the characteristics of recovery from anesthesia in the ECT setting (i.e. vital sign parameters such as blood pressure and heart rate, quality of recovery, etc.).

Timeline

Start
2015-10
Primary completion
2019-05
Completion
2019-05

Outcome

Missed primary endpoint

paper No difference was found between groups with respect to the primary or secondary outcomes. PMID 34076068 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.2 mg/kg Intravenous
Subject Ketamine Small molecule 0.5 mg/kg Intravenous

Indications